Abstract:Since the establishment of bacteria-laden plaque as a causative agent in gingivitis, the search for specific bacteria that induce different types of periodontitis has generated extensive research. In contrast to many other microbial-induced disorders, the specific periodontal pathogen(s) has not been identified to date. Therefore, the search for an effective systemic agent to prevent the loss of attachment through the selective reduction of known periodontal pathogens has remained elusive. It is not surprising then that antibiotics are not used solely to manage periodontal diseases but rather as an adjunct to the mechanical débridement of root surfaces in select periodontal diseases. Further, the sole use of antibiotics in patients with adult periodontitis (or those who exhibit signs of inflammation but are periodontally stable) has shown little benefit and only increases the chance of microbial resistance to antibiotics. Despite these limitations, considerable progress in antibiotic therapy has delivered regimens that enhance the effectiveness of conventional therapy. In contrast to traditional antimicrobial therapy, new treatment modalities have begun to focus on modulating the responses of host cells to bacteria rather than modulating only the bacteria. Current drugs used to regulate host cells inhibit the cyclooxygenase pathway, reduce the activity of metalloproteinases, or inactivate bone resorptive cells (see Table 1). Although these drugs offer great potential to modulate a variety of mammalian cells, a notable and consequential limitation of these agents is a lack of specificity. Inflammation, bone metabolism, and connective tissue metabolism are two-edged swords; all are necessary for the homeostasis of the tissue, but some or all may also be involved in the pathologic destruction of that same tissue. Hence, drugs that inhibit destruction of the connective tissue in one site of the periodontium also interfere with wound healing at another. As a result of these limitations, the efficacy, safety, and cost-effectiveness of the long-term use of these agents is unknown. Preliminary results of treatment with these drugs are promising, and future generations of host-modulating drugs will provide clinicians with additional agents to help improve the success rate of periodontal treatment for patients. Antibiotics remain an important adjunctive therapy in the treatment of periodontal diseases, and the use of host modulating drugs as supplemental agents in the management of periodontal diseases continues to grow. As more knowledge is gained about the causes of periodontal diseases, new drugs that are potent, effective, site specific, and safe can be delivered at optimal times by simply having the patient take a few tablets. Considering the dramatic progress in the past decade in understanding the cause and pharmacologic management of periodontal diseases, the twenty-first century holds great promise for the development of magic bullets.

Monitoring the periodontal microbiota as an adjunct to periodontal therapy: rationale, interpretation of test results and application to patient management

Microbial colonization of the periodontal pocket and its significance for periodontal therapy

Microbial diagnostics in periodontal diseases

Therapeutic Strategies and Genetic Implications for Periodontal Disease Management: A Systematic Review

Efficient antimicrobial treatment in periodontal maintenance care

Effect of Adjunctive Systemic Antibiotics on Microbial Populations Compared with Scaling and Root Planing Alone for the Treatment of Periodontitis: A Pilot Randomized Clinical Trial.

Nonsurgical Periodontal Treatment Options and Their Impact on Subgingival Microbiota

Antibiotic resistance in the microbiota of periodontitis patients: an update of current findings

The association between periodontal microbial biomarkers and primary therapy outcome

Microbiome changes in young periodontitis patients treated with adjunctive metronidazole and amoxicillin

Pharmacologic management of periodontal diseases using systemically administered agents

Effect of Periodontitis and Periodontal Therapy on Oral and Gut Microbiota

Europe's contribution to the evaluation of the use of systemic antimicrobials in the treatment of periodontitis

Decision‐making on systemic antibiotics in the management of periodontitis: A retrospective comparison of two concepts

Impact of periodontal therapy on oral bacterial composition in individuals diagnosed with advanced periodontal disease

Dynamic changes in the subgingival microbiome and their potential for diagnosis and prognosis of periodontitis

Comparative Study of Systemic vs. Local Antibiotics with Subgingival Instrumentation in Stage III–IV Periodontitis: A Retrospective Analysis

Diagnostic measures for monitoring and follow-up in periodontology and implant dentistry

Bacterial resistance to minocycline after adjunctive minocycline microspheres during periodontal maintenance: A randomized clinical trial

Antimicrobials in periodontal maintenance

Assessment of the Effect on Periodontitis of Antibiotic Therapy and Bacterial Lysate Treatment